FDA announcements or Johnson & Johnson's official press releases

Johnson & Johnson Acquires Rights to $1.25 Billion IL4RxIL31 Eczema Treatment

May 28, 2024, 02:55 PM

Johnson & Johnson announced on Tuesday that it has agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for approximately $1.25 billion. The treatment is a bispecific antibody designed to address atopic dermatitis by targeting two biological pathways associated with inflammation and itching. This acquisition marks Johnson & Johnson's second immunology deal this month, highlighting the company's strategic focus on expanding its immunology portfolio. The bispecific antibody, identified as IL4RxIL31, is in the clinical-stage and is expected to provide a novel approach to treating eczema.